CM-227

Discussion in 'Bristol-Myers Squibb' started by anonymous, Feb 7, 2018 at 7:55 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    more smoke and mirrors...
     

  2. anonymous

    anonymous Guest

    Another fucking dumbass on Cafepharma not knowing anything about anything.
     
  3. anonymous

    anonymous Guest

     
  4. anonymous

    anonymous Guest

    Points will be deducted for incompetent use of the quote function
    Semi literate kock
     
  5. anonymous

    anonymous Guest

    CM-227. Bahahaha.
     
  6. anonymous

    anonymous Guest

    Yes it's true.
     
  7. anonymous

    anonymous Guest

    BR-549
     
  8. anonymous

    anonymous Guest

    FU-2
     
  9. anonymous

    anonymous Guest

    Saw where a rep reposted CM227 story on linkedin, what a dumbass. Should be an opening in that territory soon.
     
  10. anonpymous

    anonpymous Guest

    Yes seeing how neither drug is approved in 1L NSCLC, I'd say that was not very smart AC. You should go ahead and inform your manager right away.

    .... Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)
     
  11. anonymous

    anonymous Guest

    joke trial.
     
  12. anonymous

    anonymous Guest

    All I can say is that the stocks of BMS and Merck have moved in the opposite directions since the trial news came out.
     
  13. anonymous

    anonymous Guest

    BMS takeover rumors? Hello McFly
     
  14. anonymous

    anonymous Guest

    BMS takeover rumors have been out there as long as one can remember. This may have gained momentum based on positive 227 study related news. Curiously though, Merck stock has declined after this news broke.
     
  15. anonymous

    anonymous Guest

    Try 867-5309.
     
  16. anonymous

    anonymous Guest

    Let the FDA do its job and make the determination.